Facebook X (Twitter) Instagram
    Facebook Instagram Threads
    Global BiodefenseGlobal Biodefense
    Subscribe
    • Featured News
    • Funding
    • Directory
    • Jobs
    • Events
    Global BiodefenseGlobal Biodefense
    Biodetection

    RFI – Identification of Diagnostic Devices for Biological Threats

    By Global Biodefense StaffMarch 13, 2014
    Share
    Facebook LinkedIn Reddit Email
    Joint Project Manager - Medical Countermeasure Systems (JPM-MCS)

    The Department of Defense is collecting information from companies who are currently in the U.S. domestic healthcare market or are considering a future entry into the market for FDA-cleared diagnostics for human diseases caused by exposure to biological threat agents.

    The Request for Information (RFI) submission period originally closed in January of this year but has now been extend to April 30, 2014. The RFI is managed by the Joint Project Management Office for Medical Countermeasure Systems (JPM-MCS) in support of the Joint Product Director for Diagnostics (JPdM Dx).

    JPM-MCS is specifically interesting in information about systems that are complementary to the Increment 1 Next Generation Diagnostic System (NGDS) sample-to-answer molecular (PCR) diagnostic platform used in forward deployed clinical laboratories, combat support hospitals and ships.

    Information gathered will be reviewed as part of a market survey in support of the NGDS Increment 2 acquisition program.

    The RFI details minimum threshold and ideal system characteristics including:

    • Portable, total system weight 0.5 lbs -15 lbs
    • Safe for use with BSL 4 agents (low risk of aerosolizing sample material)
    • Open Architecture supporting 3rd party assay design and development
    • Single Sample Time to Result objective of 5 minutes, no more than 30 minutes
    • Electronically enabled for data archiving and communications
    • Detection of agent specific proteins and biomolecules
    • Detection of disease specific host biomarkers
    • High specificity
    • Supportive of syndrome based diagnostics with endemic diseases
    • Aligned with vaccines and therapeutics in production or development
    • Exiting or emerging FDA regulatory framework for 510k clearance
    • Single use consumable or reusable, adaptable instrument/assay based system
    • FDA cleared for in-vitro diagnostics, or:
    • Sufficiently mature to begin FDA Clinical Trials within 2 years

    JPM-MCS is part of the Joint Program Executive Office for Chemical and Biological Defense (JPEO-CBD).

    Further details are available under Solicitation Number: Solicitation Number: W911QY-13-RFI-NGDSI2.

    Biomarkers Chemical Detection JPEO-CBRND POC Diagnostics RFI
    Share. Facebook LinkedIn Reddit Email
    Previous ArticleJUPITR Biosurveillance Program Takes Shape on Korean Peninsula
    Next Article Dstl Advancing Infrared Detection Technologies

    Related Stories

    New Method Improves Quantification of Ricin in Complex Matrices

    September 20, 2023

    Terrorism and the Pandemic: Weaponizing a Public Health Crisis

    September 20, 2023

    Biomarkers for Detection of Exposure to Nitrogen Mustards

    September 20, 2023

    Mount Sinai to Lead Development of Pan-Coronavirus Vaccine Under New Federal Grant

    September 17, 2023
    News Scan

    Biodefense Headlines – 19 September 2023

    News Scan September 19, 2023

    News highlights on health security threats and countermeasures curated by Global Biodefense This week’s selections include a global survey of gain-of-function research; funding of an mRNA mpox vaccine; Nipah virus outbreak in India; field detection of threat agents with acoustic…

    Upcoming Events

    Oct 3
    Virtual Event Virtual Event
    October 3 - October 5

    OneLab Summit 2023

    Oct 4
    Virtual Event Virtual Event
    10:00 am - 2:00 pm EDT

    Tunneling Nanotubes and Intracellular Protrusions Workshop

    Oct 12
    Virtual Event Virtual Event
    12:00 pm - 2:00 pm EDT

    Public-Private Partnerships for Acceptance and Uptake of Medical Countermeasures

    Oct 17
    Virtual Event Virtual Event
    12:00 pm - 2:00 pm EDT

    Public-Private Partnerships for Dispensing and Administration of Medical Countermeasures

    View Calendar

    Subscribe to Global Biodefense

    Get the latest news on pathogens and preparedness

    © 2023 Stemar Media Group LLC
    • About
    • Contact
    • Privacy
    • Subscribe

    Type above and press Enter to search. Press Esc to cancel.